Abstract
3-(4-Geranyloxy-3-methoxyphenyl)-2-trans propenoic acid is a secondary metabolite biosynthetically related to ferulic acid in which a geranyl chain is attached to the phenolic group, extracted from Acronychia baueri Schott (Fam. Rutaceae). In the last five years some of the pharmacological properties of 3-(4-geranyloxy-3-methoxyphenyl)-2-trans propenoic acid and its semisynthetic derivatives began to be characterized. In particular the ethyl ester showed a series of interesting biological effects such colon and tongue cancers chemoprevention by dietary feeding in rats and other effects closely related to cancer growth and development. Then 3-(4-geranyloxy-3-methoxyphenyl)-2-trans propenoic acid becomes a novel candidate as chemopreventive drug for the cure of various types of cancer and synthesis of some novel derivatives of 3-(4-geranyloxy-3-methoxyphenyl)-2-trans propenoic acid, other than esters, has been recently reported. The aim of this review is to examine in detail the properties of the title compound so far reported in the literature from a chemical and pharmacological point of view.
Keywords: Acronychia baueri, Anticancer activity, Ferulic acid derivatives, 3-(4'-Geranyloxy-3'-methoxyphenyl)-2-trans propenoic acid, Rutaceae
Anti-Cancer Agents in Medicinal Chemistry
Title: 3-(4-Geranyloxy-3-Methoxyphenyl)-2-trans Propenoic Acid: A Novel Promising Cancer Chemopreventive Agent
Volume: 6 Issue: 6
Author(s): Massimo Curini, Francesco Epifano, Salvatore Genovese, Maria Carla Marcotullio and Luigi Menghini
Affiliation:
Keywords: Acronychia baueri, Anticancer activity, Ferulic acid derivatives, 3-(4'-Geranyloxy-3'-methoxyphenyl)-2-trans propenoic acid, Rutaceae
Abstract: 3-(4-Geranyloxy-3-methoxyphenyl)-2-trans propenoic acid is a secondary metabolite biosynthetically related to ferulic acid in which a geranyl chain is attached to the phenolic group, extracted from Acronychia baueri Schott (Fam. Rutaceae). In the last five years some of the pharmacological properties of 3-(4-geranyloxy-3-methoxyphenyl)-2-trans propenoic acid and its semisynthetic derivatives began to be characterized. In particular the ethyl ester showed a series of interesting biological effects such colon and tongue cancers chemoprevention by dietary feeding in rats and other effects closely related to cancer growth and development. Then 3-(4-geranyloxy-3-methoxyphenyl)-2-trans propenoic acid becomes a novel candidate as chemopreventive drug for the cure of various types of cancer and synthesis of some novel derivatives of 3-(4-geranyloxy-3-methoxyphenyl)-2-trans propenoic acid, other than esters, has been recently reported. The aim of this review is to examine in detail the properties of the title compound so far reported in the literature from a chemical and pharmacological point of view.
Export Options
About this article
Cite this article as:
Curini Massimo, Epifano Francesco, Genovese Salvatore, Carla Marcotullio Maria and Menghini Luigi, 3-(4-Geranyloxy-3-Methoxyphenyl)-2-trans Propenoic Acid: A Novel Promising Cancer Chemopreventive Agent, Anti-Cancer Agents in Medicinal Chemistry 2006; 6 (6) . https://dx.doi.org/10.2174/187152006778699149
DOI https://dx.doi.org/10.2174/187152006778699149 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development of Peptides as Potential Drugs for Cancer Therapy
Current Pharmaceutical Design Cetuximab Immunoliposomes Enhance Delivery of 5-FU to Skin Squamous Carcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry Comprehensive Analysis Reveals GPRIN1 is a Potential Biomarker for Non-sm all Cell Lung Cancer
Current Bioinformatics Comparison Between the Maximum Standard Uptake Value and the Ratio of Lymph Node to Primary Tumor Attenuation in Head and Neck Cancers: A Prospective Study
Current Medical Imaging The Role of CD40 Expression in Dendritic Cells in Cancer Biology; A Systematic Review
Current Cancer Drug Targets CDK Inhibitors: From the Bench to Clinical Trials
Current Drug Targets Transdermal Drug Delivery: Opportunities and Challenges for Controlled Delivery of Therapeutic Agents Using Nanocarriers
Current Drug Metabolism Small Molecular Inhibitors of p-STAT3: Novel Agents for Treatment of Primary and Metastatic CNS Cancers
Recent Patents on CNS Drug Discovery (Discontinued) Cosmeceutical Aptitudes of Azelaic Acid
Current Drug Research Reviews Bugs as Drugs: Understanding the Linkage between Gut Microbiota and Cancer Treatment
Current Drug Targets Clinical Applicability of Microarray Technology in the Diagnosis, Prognostic Stratification, Treatment and Clinical Surveillance of Cervical Adenocarcinoma
Current Pharmaceutical Design Application of Efficient Nanoparticles for Early Diagnosis and Treatment of Cancer
Current Drug Metabolism Tumor Vasculature Targeting Through NGR Peptide-Based Drug Delivery Systems
Current Pharmaceutical Biotechnology Anticancer Mechanisms of Berberine: A Good Choice for Glioblastoma Multiforme Therapy
Current Medicinal Chemistry Role of Sequence Variations in <i>AhR</i> Gene Towards Modulating Smoking Induced Lung Cancer Susceptibility in North Indian Population: A Multiple Interaction Analysis
Current Genomics Resveratrol as an Enhancer of Apoptosis in Cancer: A Mechanistic Review
Anti-Cancer Agents in Medicinal Chemistry ROS-Responsive Nanomedicine: Towards Targeting the Breast Tumor Microenvironment
Current Medicinal Chemistry Resveratrol, a Phytochemical Inducer of Multiple Cell Death Pathways: Apoptosis, Autophagy and Mitotic Catastrophe
Current Medicinal Chemistry Oxaliplatin-mediated Inhibition of Survivin Increases Sensitivity of Head and Neck Squamous Cell Carcinoma Cell Lines to Paclitaxel
Current Cancer Drug Targets Modern drug delivery systems for targeting the posterior segment of the eye
Current Pharmaceutical Design